BioPharma Drug Discovery

FDA Approves PENBRAYA™: First Vaccine for 5 Common Meningococcal Serogroups in Teens

PENBRAYA™ provides the broadest serogroup coverage (meningococcal groups A, B, C, W and Y) of any meningococcal vaccine available in the U.S. ...

 October 23, 2023 | News

FDA Approves Pfizer's VELSIPITY™ for Severe UC in Adults

Pfizer Inc.  announced  that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selectiv...

 October 16, 2023 | News

MediLink and BioNTech Partner for Advanced Anti-Cancer Drug

Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of ...

 October 13, 2023 | News

Simplifying Drug Discovery: How Molecule AI's Empowers Researchers - An Interview with Molecule AI's Saurabh Singal

In an illuminating interview with BioPharma APAC, Saurabh Singal, the CEO-Founder of Molecule AI, delves into the transformative power of Molecule AI's pla...

 October 12, 2023 | News

TaiGen Inks Exclusive Licensing Deal for New Drug in Malaysia and Singapore

TaiGen indicates that the agreement involves the development and marketing rights of the new drug in Malaysia and Singapore. Y.S.P...

 October 12, 2023 | News

Suvoda Enhances IRT for Precise Clinical Trial Drug Supply

 Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system...

 October 12, 2023 | News

Fujitsu and RIKEN develop AI drug discovery technology utilizing generative AI to predict structural changes in proteins

Fujitsu Limited and the HPC- and AI-driven Drug Development Platform Division of the RIKEN Center for Computational Science today announced that they have ...

 October 11, 2023 | News

Dirk Lange Reveals Merck's Historic Leap as the First CTDMO to Offer Integrated mRNA Services: A Blueprint for Advancing Biopharma

In this interview, we explore the significance of Merck's €1 billion investment in advancing mRNA technologies, the impact of their acqu...

 October 11, 2023 | News

CANbridge's CAN108 (LIVMARLI®) Receives Approval in Taiwan for ALGS-Related Pruritus

CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development ...

 October 09, 2023 | News

Innovent Initiates Phase 3 Study of Efdamrofusp Alfa for Age-related Macular Degeneration

nnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

 October 09, 2023 | News

FDA Grants Orphan Drug Status to GC Biopharma's Thrombocytopenic Purpura Drug in South Korea

When designated as an orphan drug, there are incentives such as tax credits for clinical development costs and exemptions from PDUFA user fees Initial Pedi...

 October 06, 2023 | News

Akeso and RemeGen Team Up for Gastric Cancer Therapy Study

On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/0...

 October 02, 2023 | News

Hong Kong's Akeso Receives FDA IND Clearance for AK117 in MDS Combo with Azacitidine

The upcoming study, known as a randomized, double-blind, global multi-center Phase II study, is set to be conducted in the United States. Based on th...

 September 29, 2023 | News

Mabwell Starts Phase Ib/II Trial for Nectin-4 ADC with PD-1 Inhibitor

The clinical trial (CTR20232677) is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetic profile of 9MW2821 in combination with ...

 September 29, 2023 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close